FGF23 induces left ventricular hypertrophy

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Prevalence of Chronic Kidney Disease in the United States

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566

Fibroblast growth factors.

Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985

Cellular signaling by fibroblast growth factor receptors

Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923

Regulation of cardiac hypertrophy by intracellular signalling pathways

Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890

Receptor Specificity of the Fibroblast Growth Factor Family

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871

Cardiovascular Risk and Mineral Bone Disorder in Patients with Chronic Kidney Disease

Staude, H., Jeske, S., Schmitz, K., Warncke, G., & Fischer, D. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000343402 · Cited by 39

FGF23 and mineral metabolism, implications in CKD-MBD.

Rodríguez, M., López, I., Muñoz, J., Aguilera‐Tejero, E., & Almadén, Y. (2012) · PubMed · doi:10.3265/nefrologia.pre2012.mar.11415 · Cited by 37

A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age‐related and kidney diseases

Alharbi, K. S., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Kazmi, I. A., Al-Abbasi, F. A., Alzarea, S. I., Makeen, H. A., & Albratty, M. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14471 · Cited by 36

Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology

Junho, C. V. C., Frisch, J., Soppert, J., Wollenhaupt, J., & Noels, H. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad085 · Cited by 36

Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease

Ogata, E., Sugawara, H., Yamamoto, M., & Ito, H. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22012 · Cited by 38

Dietary phosphorus, serum phosphorus, and cardiovascular disease

Menon, M. C., & Ix, J. H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12283 · Cited by 35

Left Ventricular Mass Progression despite Stable Blood Pressure and Kidney Function in Stage 3 Chronic Kidney Disease

Seifert, M. E., Fuentes, L. D. L., Ginsberg, C., Rothstein, M., Dietzen, D. J., Cheng, S. C., Ross, W. R., Windus, D. W., Dávila‐Román, V. G., & Hruska, K. A. (2014) · American Journal of Nephrology · doi:10.1159/000362251 · Cited by 36

Insights From Genetic Disorders of Phosphate Homeostasis

Christov, M., & Jüppner, H. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.015 · Cited by 37

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?

Negri, A. L., & Ureña, P. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu139 · Cited by 36

Diagnostik und Therapie der chronischen Nierenerkrankung

Girndt, M. (2017) · Der Internist · doi:10.1007/s00108-017-0195-2 · Cited by 43

Genetic background influences cardiac phenotype in murine chronic kidney disease

Neuburg, S., Dussold, C., Gerber, C., Wang, X., Francis, C. P., Qi, L., David, V., Wolf, M. S., & Martin, A. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx332 · Cited by 36

Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults

Panwar, B., Judd, S. E., Wadley, V. G., Jenny, N. S., Howard, V. J., Safford, M. M., & Gutiérrez, O. M. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0139 · Cited by 36

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

Block, G. A., Rosenbaum, D. P., Yan, A. T.-K., Greasley, P. J., Chertow, G. M., & Wolf, M. S. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy061 · Cited by 36

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy

Friedl, C., & Zitt, E. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s134103 · Cited by 36

Extracellular phosphate sensing in mammals: what do we know?

Beck, L., & Beck-Cormier, S. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0121 · Cited by 38

Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

Bansal, N., Zelnick, L. R., Soliman, E. Z., Anderson, A. H., Christenson, R. H., deFilippi, C. R., Deo, R., Feldman, H. I., He, J., Ky, B., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.09.021 · Cited by 36

Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone

Hanudel, M. R., Wong, S. F., Jung, G., Qiao, B., Gabayan, V. R., Zuk, A., & Ganz, T. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.019 · Cited by 38

Chronic kidney disease measures for cardiovascular risk prediction

Mok, Y., Ballew, S. H., & Matsushita, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.007 · Cited by 37

X-linked hypophosphataemia

Kamenický, P., Briot, K., Munns, C. F., & Linglart, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01305-9 · Cited by 35

The importance of klotho in phosphate metabolism and kidney disease

Tan, S., Smith, E. R., Hewitson, T. D., Holt, S. G., & Toussaint, N. D. (2014) · Nephrology · doi:10.1111/nep.12268 · Cited by 35

Risk of Sudden Cardiac Death in Chronic Kidney Disease

Poulikakos, D. J., Banerjee, D., & Malík, M. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12328 · Cited by 35

Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease

Goto, S., Nakai, K., Kono, K., Yonekura, Y., Ito, J., Fujii, H., & Nishi, S. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-014-0947-4 · Cited by 36

The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia

Hassan, A., Durlacher, K., Silver, J., Naveh‐Many, T., & Levi, R. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00332.2015 · Cited by 35

Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes

Huang, S.-Y., Chen, Y., Kao, Y., HSIEH, M., Lin, Y., Chung, C., Lee, T.-I., Tsai, W., Chen, S., & Chen, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12470 · Cited by 34

Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3

Shardlow, A., McIntyre, N. J., Fluck, R., McIntyre, C. W., & Taal, M. W. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016528 · Cited by 37

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Kassianides, X., & Bhandari, S. (2021) · Drugs in Context · doi:10.7573/dic.2020-11-3 · Cited by 39

Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome

Hao, H., Ma, S., Zheng, C., Wang, Q., Lin, H., Chen, Z., Xie, J., Chen, L., Chen, K., Wang, Y., et al. (2021) · Aging · doi:10.18632/aging.202448 · Cited by 35

Fibroblast Growth Factor 23 Stimulates Cardiac Fibroblast Activity through Phospholipase C-Mediated Calcium Signaling

Lee, T., Chung, C., Lee, T.-I., Lin, Y., Kao, Y., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010166 · Cited by 36

Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation

Courbon, G., Thomas, J. J., Martínez‐Calle, M., Wang, X., Spindler, J. J., Drasek, J. C. V., Hunt-Tobey, B., Mehta, R. C., Isakova, T., Chang, W., et al. (2023) · Blood · doi:10.1182/blood.2022018475 · Cited by 36

Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis

Hsu, J. J., Katz, R., Ix, J. H., de Boer, I. H., Kestenbaum, B. R., & Shlipak, M. G. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu101 · Cited by 35

The fibroblast growth factor‐23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk

Masson, S., Agabiti, N., Vago, T., Miceli, M., Mayer, F., Letizia, T., Wienhues‐Thelen, U., Mureddu, G. F., Davoli, M., Boccanelli, A., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12232 · Cited by 35

Very low protein diet enhances inflammation, malnutrition, and vascular calcification in uremic rats

Yamada, S., Tokumoto, M., Tatsumoto, N., Tsuruya, K., Kitazono, T., & Ooboshi, H. (2016) · Life Sciences · doi:10.1016/j.lfs.2015.12.050 · Cited by 35

Assessment and management of heart failure in patients with chronic kidney disease

Guaricci, A. I., Sturdà, F., Russo, R., Basile, P., Baggiano, A., Mushtaq, S., Fusini, L., Fazzari, F., Bertandino, F., Monitillo, F., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10346-x · Cited by 39

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure

Phan, O., Maillard, M. P., Malluche, H. H., Stehle, J., Funk, F., & Burnier, M. (2015) · BioMed Research International · doi:10.1155/2015/515606 · Cited by 34

A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease

Masai, H., Joki, N., Sugi, K., & Moroi, M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.045 · Cited by 34

Hypophosphatemic Rickets: Revealing Novel Control Points for Phosphate Homeostasis

White, K. E., Hum, J. M., & Econs, M. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0223-2 · Cited by 34

Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?

Fukumoto, S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00048 · Cited by 34

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism

Susantitaphong, P., Vadcharavivad, S., Susomboon, T., Singhan, W., Dumrongpisutikul, N., Jakchairoongruang, K., Eiam‐Ong, S., & Praditpornsilpa, K. (2019) · Renal Failure · doi:10.1080/0886022x.2018.1562356 · Cited by 34

Klotho regulation by albuminuria is dependent on ATF3 and endoplasmic reticulum stress

Delitsikou, V., Jarad, G., Rajaram, R. D., Ino, F., Rutkowski, J. M., Chen, C.-D., Santos, C. X. C., Scherer, P. E., Abraham, C. R., Shah, A. M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900893r · Cited by 34

Fibroblast growth factor 23: are we ready to use it in clinical practice?

Krijger, A. B.-D., & Vervloet, M. G. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00715-2 · Cited by 35

Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study

Fischer, D.-C., Smith, C. J., Zan, F. D., Bacchetta, J., Bakkaloglu, S. A., Ağbaş, A., Anarat, A., Aoun, B., Askiti, V., Ažukaitis, K., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.025 · Cited by 37

Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives

McCarty, M. F., & DiNicolantonio, J. J. (2013) · Nutrition · doi:10.1016/j.nut.2013.12.010 · Cited by 36

Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo

Pereira, R. C., Delany, A. M., Khouzam, N. M., Bowen, R. E., FREYMILLER, E. G., Salusky, I. B., & Wesseling‐Perry, K. (2014) · Kidney International · doi:10.1038/ki.2014.347 · Cited by 33

Arterial stiffness in chronic kidney disease

Taal, M. W. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000441153.40072.e0 · Cited by 33

αKlotho–FGF23 interactions and their role in kidney disease: a molecular insight

Smith, E. R., Holt, S. G., & Hewitson, T. D. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03241-y · Cited by 33

High‐intensity interval training increases myocardial levels of Klotho and protects the heart against ischaemia–reperfusion injury

Ramez, M., Ramezani, F., Nasirinezhad, F., & Rajabi, H. (2020) · Experimental Physiology · doi:10.1113/ep087994 · Cited by 33

C-FGF23 peptide alleviates hypoferremia during acute inflammation

Agoro, R., Park, M. Y., Hénaff, C. L., Jankauskas, S. S., Gaias, A., Chen, G., Mohammadi, M., & Sitara, D. (2020) · Haematologica · doi:10.3324/haematol.2019.237040 · Cited by 34

Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy

Law, J. P., Price, A. M., Pickup, L. C., Radhakrishnan, A., Weston, C. J., Jones, A. M., McGettrick, H. M., Chua, W., Steeds, R. P., Fabritz, L., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016041 · Cited by 34

Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects

Lindner, M., Mehel, H., David, A., Leroy, C., Burtin, M., Friedlander, G., Terzi, F., Mika, D., Fischmeister, R., & Prié, D. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-0810-6 · Cited by 33

Klotho Protein and Cardio-Vascular System

Tyurenkov, I. N., Perfilova, V. N., Нестерова, А. А., & Glinka, Y. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921020024 · Cited by 34

How FGF23 shapes multiple organs in chronic kidney disease

Leifheit‐Nestler, M., & Haffner, D. (2021) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-021-00123-x · Cited by 36

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

Lu, W., Xiao, W., Xie, W., Fu, X., Pan, L., Jin, H., Yu, Y., Zhang, Y., & Li, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.735374 · Cited by 36

Fibroblast growth factor 23--structure, function and role in kidney diseases.

Kocełak, P., Olszanecka‐Glinianowicz, M., & Chudek, J. T. (2012) · PubMed · Cited by 33

Vitamin D and Heart Failure

Brinkley, D. M., Ali, O. M., ZALAWADIYA, S. K., & Wang, T. J. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0355-7 · Cited by 34

Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease

Lerch, C., Shroff, R. C., Wan, M., Rees, L., Aitkenhead, H., Bulut, İ. K., Thurn, D., Bayazıt, A. K., Niemirska, A., Canpolat, N., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy012 · Cited by 33

Mineral (Mal)Adaptation to Kidney Disease—Young Investigator Award Address

Wolf, M. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04430415 · Cited by 34

Fibroblast Growth Factor 23

Hardcastle, M., & Dittmer, K. E. (2015) · Veterinary Pathology · doi:10.1177/0300985815586222 · Cited by 32

Regression of vascular calcification in chronic kidney disease – feasible or fantasy? A review of the clinical evidence

Leonard, O., Spaak, J., & Goldsmith, D. J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12014 · Cited by 32

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

Ureña, P., Prié, D., Keddad, K., Preston, P. E., Wilde, P., Wan, H. I., & Copley, J. B. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-71 · Cited by 32

A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients

Craver, L., Dusso, A., Martínez‐Alonso, M., Sarró, F., Valdivielso, J. M., & Fernández, E. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-221 · Cited by 32

Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area

Shah, N. H., Dong, C., Elkind, M. S. V., Sacco, R. L., Mendez, A. J., Hudson, B. I., Silverberg, S. J., Wolf, M. S., Rundek, T., & Wright, C. B. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305945 · Cited by 32

Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial

Chang, A. R., Miller, E. R., Anderson, C. A. M., Juraschek, S. P., Melough, M. M., White, K. N., Henry-Barron, B. J., Krekel, C., Oh, S., Charleston, J. B., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.08.029 · Cited by 32

Impact of vascular calcification on cardiovascular mortality in hemodialysis patients: clinical significance, mechanisms and possible strategies for treatment

Ohtake, T., & Kobayashi, S. (2017) · Renal Replacement Therapy · doi:10.1186/s41100-017-0094-y · Cited by 32

Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction

Schumacher, D., Alampour‐Rajabi, S., Ponomariov, V., Curaj, A., Wu, Z., Staudt, M., Rusu, M., Jankowski, V., Marx, N., Jankowski, J., et al. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.02.001 · Cited by 32

Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study

Eisenga, M. F., de Jong, M. A., van der Meer, P., Leaf, D. E., Huls, G. A., Nolte, I. M., Gaillard, S., Bakker, S. J. L., & de Borst, M. H. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002818 · Cited by 34

Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under‐diagnosed disease

Prastaro, M., Nardi, E., Paolillo, S., Santoro, C., Parlati, A. L. M., Gargiulo, P., Basile, C., Buonocore, D., Esposito, G., & Filardi, P. P. (2022) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23265 · Cited by 32

Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Bacchetta, J., Salusky, I. B., & Hewison, M. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2336-0 · Cited by 32

Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials

Patel, R. B., & Shah, S. J. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021136 · Cited by 31

Non-Classical Effects of FGF23: Molecular and Clinical Features

Martínez-Heredia, L., Moreno, J. M. C., García-Fontana, B., & Muñoz‐Torres, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094875 · Cited by 37

FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease

Ketteler, M., Biggar, P. H., & Liangos, O. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs557 · Cited by 31

Enhanced FGF23 production in mice expressing PI3K‐insensitive GSK3 is normalized by β‐blocker treatment

Fajol, A., Chen, H., Umbach, A. T., Quarles, L. D., Lang, H., & Föller, M. (2015) · The FASEB Journal · doi:10.1096/fj.15-279943 · Cited by 32

Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices

Yang, K., Peretz‐Soroka, H., Wu, J., Zhu, L., Cui, X., Zhang, M., Rigatto, C., Liu, Y., & Lin, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-03210-0 · Cited by 31

Alpha Klotho and Fibroblast Growth Factor-23 Among Alcoholics

Quintero‐Platt, G., González‐Reimers, E., Rodrı́guez-Gaspar, M., Martín-González, C., Pérez‐Hernández, O., Romero-Acevedo, L., Espelosín-Ortega, E., de la Vega-Prieto, M. J., & Santolaria-Fernández, F. J. (2017) · Alcohol and Alcoholism · doi:10.1093/alcalc/agx041 · Cited by 31

Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders

Komaba, H., Wang, M., Taniguchi, M., Yamamoto, S., Nomura, T., Schaubel, D. E., Smith, A. R., Zee, J., Karaboyas, A., Bieber, B. A., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13091216 · Cited by 31

Adenine-Induced Chronic Renal Failure in Rats: A Model of Chronic Renocardiac Syndrome with Left Ventricular Diastolic Dysfunction but Preserved Ejection Fraction

Kashioulis, P., Lundgren, J., Shubbar, E., Nguy, L., Saeed, A., Guron, C. W., & Guron, G. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000491056 · Cited by 31

A Control Region Near the Fibroblast Growth Factor 23 Gene Mediates Response to Phosphate, 1,25(OH)2D3, and LPS In Vivo

Lee, S. M., Carlson, A. H., Onal, M., Benkusky, N. A., Meyer, M. B., & Pike, J. W. (2019) · Endocrinology · doi:10.1210/en.2019-00622 · Cited by 31

Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study

Komaba, H., Fuller, D. S., Taniguchi, M., Yamamoto, S., Nomura, T., Zhao, J., Bieber, B. A., Robinson, B. M., Pisoni, R. L., & Fukagawa, M. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.08.013 · Cited by 31

The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders

Takashi, Y., & Kawanami, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042376 · Cited by 30

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

Boots, J. M. M., & Quax, R. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01216-w · Cited by 31

Calcium Regulation and Bone Mineral Metabolism in Elderly Patients with Chronic Kidney Disease

Tejwani, V., & Qian, Q. (2013) · Nutrients · doi:10.3390/nu5061913 · Cited by 33

Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4–5

Gravesen, E., Hofman-Bang, J., Lewin, E., & Ølgaard, K. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.744464 · Cited by 31

PAI-1 is a critical regulator of FGF23 homeostasis

Eren, M., Place, A. T., Thomas, P. M., Flevaris, P., Miyata, T., & Vaughan, D. E. (2017) · Science Advances · doi:10.1126/sciadv.1603259 · Cited by 31

‘Phos’tering a Clear Message: The Evolution of Dietary Phosphorus Management in Chronic Kidney Disease

Biruete, A., Gallant, K. M. H., Lloyd, L., Meade, A., Moe, S. M., St‐Jules, D. E., & Kistler, B. M. (2023) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2023.05.004 · Cited by 31

Current and Novel Biomarkers in Cardiogenic Shock

Galusko, V., Wenzl, F. A., Vandenbriele, C., Panoulas, V. F., Lüscher, T. F., & Gorog, D. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3531 · Cited by 31

Phosphate: a novel cardiovascular risk factor

Ketteler, M., Wolf, M., Hahn, K., & Ritz, E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs247 · Cited by 30

The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease

Wald, R., Goldstein, M. B., Perl, J. M., Kiaii, M., Yuen, D. A., Wald, R. M., Harel, Z., Weinstein, J. J., Jakubovic, B. D., Leong-Poi, H. M., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.07.004 · Cited by 30

Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus

Freedman, B. I., Divers, J., Russell, G. B., Bowden, D. W., Carr, J. J., Wagenknecht, L. E., Hightower, R. C., Xu, J., Smith, S. C., Langefeld, C. D., et al. (2015) · American Journal of Nephrology · doi:10.1159/000443241 · Cited by 30

Intersection of cardiovascular disease and kidney disease

Bansal, N., Hsu, C., & Go, A. S. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000444820.80249.56 · Cited by 30

Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets

Wacker, M., Touchberry, C. D., Silswal, N., Brotto, L. S., Elmore, C. J., Bonewald, L. F., Andresen, J. J., & Brotto, M. A. P. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00173 · Cited by 31

Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene

Han, X., Ross, J., Kolumam, G. A., Pi, M., Sonoda, J., King, G. D., & Quarles, L. D. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040412 · Cited by 31

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease

Chertow, G. M., Block, G. A., Neylan, J. F., Pérgola, P. E., Uhlig, K., & Fishbane, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188712 · Cited by 30

Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis—Effect on Fibroblast Growth Factor-23 Metabolism

Fukao, W., Hasuike, Y., Yamakawa, T., Toyoda, K., Aichi, M., Masachika, S., Kantou, M., Takahishi, S., Iwasaki, T., Yahiro, M., et al. (2018) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2017.12.009 · Cited by 30

Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia

Hernández-Frías, O., Gil‐Peña, H., Pérez-Roldán, J. M., González-Sanchez, S., Ariceta, G., Chocrón, S., Loza, R., Ojeda, F. D. L. C., Madariaga, L., Vergara, I., et al. (2019) · Pediatric Nephrology · doi:10.1007/s00467-018-4180-3 · Cited by 30

Intact and C-Terminal FGF23 Assays—Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?

Sharma, S., Katz, R., Bullen, A. L., Chaves, P. H. M., de Leeuw, P. W., Kroon, A. A., Houben, A. J. H. M., Shlipak, M. G., & Ix, J. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa665 · Cited by 30

Vitamin D Effects on Bone Homeostasis and Cardiovascular System in Patients with Chronic Kidney Disease and Renal Transplant Recipients

Cianciolo, G., Cappuccilli, M. L., Tondolo, F., Gasperoni, L., Zappulo, F., Barbuto, S., Iacovella, F., Conte, D., Capelli, I., & Manna, G. L. (2021) · Nutrients · doi:10.3390/nu13051453 · Cited by 30

Endocrine Regulation of Extra-skeletal Organs by Bone-derived Secreted Protein and the effect of Mechanical Stimulation

Du, Y., Zhang, L., Wang, Z., Zhao, X., & Zou, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.778015 · Cited by 30

Knockout of Nuclear High Molecular Weight FGF2 Isoforms in Mice Modulates Bone and Phosphate Homeostasis

Homer-Bouthiette, C., Doetschman, T., Xiao, L., & Hurley, M. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.619569 · Cited by 33

Prognostic impact of renal function in precapillary pulmonary hypertension

Kaiser, R., Seiler, S., Held, M., Bals, R., & Wilkens, H. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12131 · Cited by 31

Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease

Sinha, M. D., Turner, C., Booth, C. J., Waller, S. C., Rasmussen, P., Goldsmith, D. J. A., & Simpson, J. M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3125-3 · Cited by 30

FGF23: Clinical usefulness and analytical evolution

Fauconnier, C., Roy, T., Gillerot, G., Roy, C., Pouleur, A., & Gruson, D. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.03.002 · Cited by 30

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy

Gutiérrez, O. M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv445 · Cited by 5

SaO027CARDIO-PATHOLOGICAL EFFECTS OF FGF23 IN CKD ARE MEDIATED BY FGFR4

Grabner, A., Amaral, A. P., Singh, S., Schramm, K. J., Sloan, A. J., Kentrup, D., Reuter, S., Pavenstaedt, H., Marco, G. S. D., Wolf, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv150.04

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD

Hidaka, N., Inoue, K., Katô, H., Hoshino, Y., Koga, M., Kinoshita, Y., Takashi, Y., Makita, N., Fukumoto, S., Nangaku, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100747 · Cited by 13

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 843